MeSH D011041 - poisoning
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D064419:Chemically-induced disorders
0 Companies
0 Drugs
Success rate
D011041:
Poisoning
D000075322:Heavy metal poisoning
0 Companies
0 Drugs
Success rate
D001733:Bites and stings
0 Companies
0 Drugs
Success rate
D002252:Carbon tetrachloride poisoning
0 Companies
0 Drugs
Success rate
D005458:Fluoride poisoning
0 Companies
0 Drugs
Success rate
D005517:Foodborne diseases
0 Companies
0 Drugs
Success rate
D005739:Gas poisoning
0 Companies
0 Drugs
Success rate
D010939:Plant poisoning
0 Companies
0 Drugs
Success rate
D011605:Substance-induced psychoses
0 Companies
0 Drugs
Success rate
D014869:Water intoxication
0 Companies
0 Drugs
Success rate
D015651:Mycotoxicosis
0 Companies
0 Drugs
Success rate
D020258:Neurotoxicity syndromes
0 Companies
0 Drugs
Success rate
D056486:Chemical and drug induced liver injury
0 Companies
0 Drugs
Success rate
D062025:Organophosphate poisoning
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Fomepizole | Fomepizole | 2008-03-03 | |||
| Merck Sharp & Dohme | Hydroxocobalamin | Alpharedisol | 1982-01-01 |
1
2
3
4
5
6
...
10
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
0%0/3
Phase 3
69%9/13
Approved: 9Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use